Does Pharmacist-Led Medication Review Improve Health Outcomes? Evaluation of a Quality Improvement Project February 19, 2015 Quality Forum Corinne M Hohl MD FRCP MHSc Attending Physician, Dept of Emergency Medicine, VGH Associate Professor, Dept of Emergency Medicine, University of British Columbia Scientist, Centre for Clinical Epidemiology and Evaluation CIHR New Investigator
24
Embed
Does Pharmacist Led Medication Review Improve Health Outcomes
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Does Pharmacist-Led Medication Review Improve Health Outcomes?
Evaluation of a Quality Improvement Project
February 19, 2015Quality Forum
Corinne M Hohl MD FRCP MHScAttending Physician, Dept of Emergency Medicine, VGHAssociate Professor, Dept of Emergency Medicine, University of British
ColumbiaScientist, Centre for Clinical Epidemiology and EvaluationCIHR New Investigator
ADE: unintended and harmful effects of medications.
• Most common cause of preventable iatrogenic morbidity.
• Patients with ADEs commonly present to EDs:– 12% of ED visits amounting to 20,000 visits per year to VCHA– 35-40% of are not attributed to medication use by MDs– 50% greater odds of spending additional days in
hospital/month.
• Leading cause of unplanned admissions.
Co-funded by BC HSPO & VCHA in 2011
Aim: To evaluate the effect of pharmacist-led medication review in high-risk ED patients on health outcomes compared to usual care (medication reconciliation).
Innovation: A new model of delivering pharmacy care to ensure that patients receive optimal medication therapy from when they arrive.
Design:– Prospective comparator study, non-
blinded that was nested within a continuous quality improvement project at 3 sites.
Population:– High-risk adults presenting to a
participating ED at a time an ADE pharmacist was present (including evenings and weekends)
Intervention: Medication Review by Clinical Pharmacists
– Best-possible medication history & initiated med reconciliation
– Review of medications critically to identify ADEs, and medication-related problems
– Communication with emergency MD/GP/geriatric triage nurse if discharged or emergency/admitting MD if admitted.
Control:– Med reconciliation by admitting/consultant services &
medication review on the ward among admitted.
• Reconciliation an accurate medication history from a variety of sources based on which medications are re-prescribed.
Aim: to avoid medication errors at care transitions.
• Review an accurate medication history followed by a structured, critical examination of a patient’s medications
Aim: to reach agreement on the goals of therapy, minimize errors, optimize medication effectiveness, identify medication-related problems and ADEs.
Outcomes:1o Proportion of days spent in hospital within 30
days of the index ED visit (encompasses index admission and days readmitted)
2o Proportion admittedUnplanned ED visits within 7dMortality (all-cause)
ED visits (VGH, LGH, RH) (n=135,323)
Excluded (n=124,516) ▪ Low-risk or unknown (n=95,837 ) ▪ Age < 19yrs (n=882) ▪ Pharmacist not available (n=22,675) ▪ CTAS=1 unknown (n=236) ▪ Multisystem Trauma (n=302) ▪ Scheduled re-visit (n=1,643) ▪ Sexual assaults (n=4) ▪ Post-operative complications (n=224) ▪ Social problems (n=317) ▪ Pregnancy-related complication (n=18) ▪ Death on arrival/in ED (n=406) ▪ Repeat visits (n=1,964) ▪ Unresolved linkage (n=1) ▪ Left Against Medical Advice/Missing data (n=9)
High-Risk eligible(n=10,805)
Med Rev (n=6,416)
Control(n=4,389)
Systematic
Allocation
Patient Flow
Med Rev (n=6,416
)
Control(n=4,389
)Median age, yrs 71 69
Female, % 56.4 55.1
Mean No. Meds 8.1 7.7
Lowest SES quintile, %
11.7 11.2
Ambulance Arrival, %
37.1 32.9
Daytime Arrival, % 61.2 61.3
Weekend Arrival, %
13.2 12.4
Baseline Characteristics – Overall
Med Rev (n=6,416
)
Control(n=4,389
)Median age, yrs 71 69
Female, % 56.4 55.1
Mean No. Meds 8.1 7.7
Lowest SES quintile, %
11.7 11.2
Ambulance Arrival, %
37.1 32.9
Daytime Arrival, % 61.2 61.3
Weekend Arrival, %
13.2 12.4
Baseline Characteristics – Overall
Median No. Hospital Days over 30 Days of Follow-Up
Difference in Days( 95% CI)
p-value
All Sites -0.48 days (-0.96 to 0.0)
0.058
<80 yrs -0.6 days (-1.17, -0.06)
0.03
Pts in the medication review group spent a median of 12h in hospital less over 30d, p=0.058
• At VGH:– n=1,928 high-risk patients whose medications were
reviewed in the ED & who were admitted.• Avoided 1041 hospital days (0.54 days/patient).• Resulted in avoided costs of $468,000 ($450/hospital day).• Costs of maintaining the program: $400,957 in pharmacy
salaries.• The cost of nursing salaries & administrative costs (IT,
coordinator, evaluation) removed after implementation period.
– Pharmacist-led medication review in ED was cost avoidant by reducing hospital days.
We have an opportunity to implement best-evidence and meet the Accreditation Canada ROP:
1. We have developed evidence-based clinical decision rules to identify high-risk ED patients, and have implemented them at VGH, LGH and RH to identify & select high-risk patients.
1. Our results suggest that if pharmacists review the medications of high-risk patients, this will lead to LOS reduction and get patients home sooner.
• Intervention was not fully optimized because of rotating staffing model: time spent on training new staff & relationship building can be reduced.
• Calculations do not take into account any other benefit of the program.